Comparative Pharmacology
Head-to-head clinical analysis: DIHYDROERGOTAMINE MESYLATE versus MIGERGOT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIHYDROERGOTAMINE MESYLATE versus MIGERGOT.
DIHYDROERGOTAMINE MESYLATE vs MIGERGOT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydroergotamine mesylate is an ergot alkaloid with potent agonist activity at serotonin 5-HT1B/1D receptors, leading to vasoconstriction of cranial blood vessels. It also has partial agonist/antagonist activity at alpha-adrenergic and dopamine receptors, contributing to its antimigraine effects.
Ergotamine is a partial agonist at serotonin (5-HT) receptors, particularly 5-HT1B/1D, and also exhibits agonism at alpha-adrenergic and dopamine receptors. It causes vasoconstriction of cranial blood vessels and reduces central pain transmission.
1 mg intramuscularly or subcutaneously, repeat at 1-hour intervals as needed, maximum 3 mg per 24 hours and 6 mg per week; intravenous use is reserved for severe cases: 0.5-1 mg IV, may repeat once after 1 hour, maximum 2 mg per 24 hours.
1 mg ergotamine tartrate and 100 mg caffeine per rectal suppository, inserted rectally at onset of headache; may repeat after 1 hour if needed, maximum 2 suppositories per headache and 5 per week.
None Documented
None Documented
Terminal half-life is approximately 9 hours (range 7-13 hours) after IM administration; clinical effect duration corresponds to this elimination phase.
Ergotamine: 2 hours (initial) with terminal half-life 21-34 hours due to enterohepatic recirculation; caffeine: 3-6 hours.
Primarily hepatic metabolism; <10% excreted unchanged in urine; biliary/fecal excretion accounts for ~90% of metabolites.
Primarily hepatic metabolism (ergotamine) with 90% biliary/fecal elimination as metabolites; less than 4% renal excretion unchanged.
Category D/X
Category C
Ergot Alkaloid
Ergot Alkaloid